Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Declares $.07 Dividend; ViaCell Deal Clears Waiting Period

NEW YORK (GenomeWeb News) — PerkinElmer’s bid to buy ViaCell has passed the Hart-Scott-Rodino antitrust waiting period, which expired yesterday.
 
Separately today, PerkinElmer declared a $.07 quarterly dividend payable on Feb. 8, 2008, to all stockholders of record at the end of Jan. 18, 2008.
 
The company is scheduled to release its quarterly earnings after the close of trading today.
 
PerkinElmer said in early October it plans to spend $300 million to buy Viacell, a Massachusetts-based company that collects and preserves umbilical cord stem cells for later use.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.